News & Updates

Sotatercept, when added to background therapy, helps improve outcomes for children with pulmonary hypertension, as shown in a retrospective study.

High levels of cardiovascular health (CVH), as defined by Life’s Essential 8 (LE8), is associated with a lower risk of developing pulmonary hypertension (PH), suggests a study. Proteomic signatures mediate this protective effect.

Tambotatug pelitecan (Tam-Peli), a novel B7-H3–targeting antibody–drug conjugate, delivers significant survival boost in relapsed small-cell lung cancer (SCLC) as compared with topotecan, according to the phase III TAISHAN-302 trial.

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Antimicrobial resistance (AMR) in ventilator-associated pneumonia and bloodstream infections in Asia is common and associated with high mortality rates and reduced quality of life, as shown in the ACORN-HAI study.